Literature DB >> 25715096

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Miguel O'Ryan1, Roberto Vidal, Felipe del Canto, Juan Carlos Salazar, David Montero.   

Abstract

In Part II we discuss the following bacterial pathogens: Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic) and Campylobacter jejuni. In contrast to the enteric viruses and Vibrio cholerae discussed in Part I of this series, for the bacterial pathogens described here there is only one licensed vaccine, developed primarily for Vibrio cholerae and which provides moderate protection against enterotoxigenic E. coli (ETEC) (Dukoral(®)), as well as a few additional candidates in advanced stages of development for ETEC and one candidate for Shigella spp. Numerous vaccine candidates in earlier stages of development are discussed.

Entities:  

Keywords:  CFU, colony-forming units; CFs, colonization factors; CT, cholera toxin; CT-B cholera toxin B subunit; Campylobacter; CtdB, cytolethal distending toxin subunit B; E. coli; EHEC; EPEC, enteropathogenic E. coli; ETEC; ETEC, enterotoxigenic E. coli; GEMS, Global enterics multicenter study; HUS, hemolytic uremic syndrome; IM, intramuscular; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; LEE, locus of enterocyte effacement; LPS, lipopolysaccharide; LT, heat labile toxin; LT-B; OMV, outer membrane vesicles; ST, heat stable toxin; STEC; STEC, shigatoxin producing E. coli; STh, human heat stable toxin; STp, porcine heat stable toxin; Salmonella; Shigella; Stx, shigatoxin; TTSS, type III secretion system; V. cholera; WHO, World Health Organization; acute diarrhea; dmLT, double mutant heat labile toxin; enteric pathogens; enterohemorrhagic E. coli; gastroenteritis; heat labile toxin B subunit; norovirus; rEPA, recombinant exoprotein A of Pseudomonas aeruginosa; rotavirus; vaccines

Mesh:

Substances:

Year:  2015        PMID: 25715096      PMCID: PMC4514228          DOI: 10.1080/21645515.2015.1011578

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  188 in total

1.  Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection.

Authors:  Manohar John; Indira T Kudva; Robert W Griffin; Allen W Dodson; Bethany McManus; Bryan Krastins; David Sarracino; Ann Progulske-Fox; Jeffrey D Hillman; Martin Handfield; Phillip I Tarr; Stephen B Calderwood
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 2.  Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors.

Authors:  Claude Parsot
Journal:  FEMS Microbiol Lett       Date:  2005-09-15       Impact factor: 2.742

3.  Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection.

Authors:  B E Rice; D M Rollins; E T Mallinson; L Carr; S W Joseph
Journal:  Vaccine       Date:  1997-12       Impact factor: 3.641

4.  Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.

Authors:  Armelle Phalipon; Corina Costachel; Cyrille Grandjean; Audrey Thuizat; Catherine Guerreiro; Myriam Tanguy; Farida Nato; Brigitte Vulliez-Le Normand; Frédéric Bélot; Karen Wright; Véronique Marcel-Peyre; Philippe J Sansonetti; Laurence A Mulard
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

5.  Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

Authors:  Robin McKenzie; Malabi M Venkatesan; Marcia K Wolf; Dilara Islam; Shannon Grahek; Andrea M Jones; Arlene Bloom; David N Taylor; Thomas L Hale; A Louis Bourgeois
Journal:  Vaccine       Date:  2008-04-16       Impact factor: 3.641

Review 6.  Assessing the existing information on the efficacy of bovine vaccination against Escherichia coli O157:H7--a systematic review and meta-analysis.

Authors:  N P Varela; P Dick; J Wilson
Journal:  Zoonoses Public Health       Date:  2012-08-01       Impact factor: 2.702

7.  Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.

Authors:  Shannon J Heine; Jovita Diaz-McNair; Abhay U Andar; Cinthia B Drachenberg; Lillian van de Verg; Richard Walker; Wendy L Picking; Marcela F Pasetti
Journal:  J Immunol       Date:  2014-01-22       Impact factor: 5.422

8.  Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge.

Authors:  Ulrike Beate Mayr; Pavol Kudela; Alena Atrasheuskaya; Eugenij Bukin; Georgy Ignatyev; Werner Lubitz
Journal:  Microb Biotechnol       Date:  2011-11-22       Impact factor: 5.813

9.  Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico.

Authors:  David A Sack; Janet Shimko; Olga Torres; August L Bourgeois; Domingo Sanchez Francia; Björn Gustafsson; Anders Kärnell; Iréne Nyquist; Ann-Mari Svennerholm
Journal:  Vaccine       Date:  2007-04-04       Impact factor: 3.641

10.  Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.

Authors:  Ronald H Behrens; Jakob P Cramer; Tomas Jelinek; Hilary Shaw; Frank von Sonnenburg; Darren Wilbraham; Thomas Weinke; David J Bell; Edwin Asturias; Hermann L Enkerlin Pauwells; Roberto Maxwell; Mercedes Paredes-Paredes; Gregory M Glenn; Shailesh Dewasthaly; Donald M Stablein; Zhi-Dong Jiang; Herbert L DuPont
Journal:  Lancet Infect Dis       Date:  2013-11-29       Impact factor: 25.071

View more
  12 in total

1.  Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

Authors:  David A Montero; Felipe Del Canto; Juan C Salazar; Sandra Céspedes; Leandro Cádiz; Mauricio Arenas-Salinas; José Reyes; Ángel Oñate; Roberto M Vidal
Journal:  NPJ Vaccines       Date:  2020-03-12       Impact factor: 7.344

2.  Surface proteome mining for identification of potential vaccine candidates against Campylobacter jejuni: an in silico approach.

Authors:  Kusum Mehla; Jayashree Ramana
Journal:  Funct Integr Genomics       Date:  2016-10-24       Impact factor: 3.410

Review 3.  Corn-based vaccines: current status and prospects.

Authors:  Sergio Rosales-Mendoza; Cristhian Sández-Robledo; Bernardo Bañuelos-Hernández; Carlos Angulo
Journal:  Planta       Date:  2017-03-27       Impact factor: 4.116

4.  Chaperone-Usher Pili Loci of Colonization Factor-Negative Human Enterotoxigenic Escherichia coli.

Authors:  Felipe Del Canto; Miguel O'Ryan; Mirka Pardo; Alexia Torres; Daniela Gutiérrez; Leandro Cádiz; Raul Valdés; Aquiles Mansilla; Rodrigo Martínez; Daniela Hernández; Benjamin Caro; Myron M Levine; David A Rasko; Christopher M Hill; Mihai Pop; O Colin Stine; Roberto Vidal
Journal:  Front Cell Infect Microbiol       Date:  2017-01-06       Impact factor: 5.293

5.  Purification and Anti-pathogenic Properties of Immunoglobulin Concentrates from Porcine Blood.

Authors:  Tae-Hwan Jung; Jae-Hwan Choi; Kyung-Chul Koh; Woo-Min Jeon; Kyoung-Sik Han
Journal:  Korean J Food Sci Anim Resour       Date:  2017-10-31       Impact factor: 2.622

6.  Evaluations of Alkyl hydroperoxide reductase B cell antigen epitope as a potential epitope vaccine against Campylobacter jejuni.

Authors:  Hongqiang Lou; Xusheng Li; Fangming Guo; Mingxing Ding; Ye Hu; Haohao Chen; Jie Yan
Journal:  Saudi J Biol Sci       Date:  2019-05-29       Impact factor: 4.219

7.  Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.

Authors:  Mark S Riddle; Robert W Kaminski; Claudio Di Paolo; Chad K Porter; Ramiro L Gutierrez; Kristen A Clarkson; Hailey E Weerts; Christopher Duplessis; Amy Castellano; Cristina Alaimo; Kristopher Paolino; Robert Gormley; Veronica Gambillara Fonck
Journal:  Clin Vaccine Immunol       Date:  2016-12-05

8.  Ontology-based literature mining of E. coli vaccine-associated gene interaction networks.

Authors:  Junguk Hur; Arzucan Özgür; Yongqun He
Journal:  J Biomed Semantics       Date:  2017-03-14

9.  Coli Surface Antigen 26 Acts as an Adherence Determinant of Enterotoxigenic Escherichia coli and Is Cross-Recognized by Anti-CS20 Antibodies.

Authors:  Leandro Cádiz; Alexia Torres; Raúl Valdés; Gabriel Vera; Daniela Gutiérrez; Myron M Levine; David A Montero; Miguel O'Ryan; David A Rasko; O Colin Stine; Roberto Vidal; Felipe Del Canto
Journal:  Front Microbiol       Date:  2018-10-16       Impact factor: 5.640

10.  Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies.

Authors:  Angelene F Richards; Jennifer E Doering; Shannon A Lozito; John J Varrone; Graham G Willsey; Michael Pauly; Kevin Whaley; Larry Zeitlin; Nicholas J Mantis
Journal:  PLoS Negl Trop Dis       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.